Autophagie
Les inhibiteurs de l'autophagie ciblent le processus cellulaire de l'autophagie, qui implique la dégradation et le recyclage des composants cellulaires via les lysosomes. L'autophagie est un mécanisme crucial pour maintenir l'homéostasie cellulaire, mais sa dérégulation est impliquée dans diverses maladies, y compris le cancer, les maladies neurodégénératives et les infections. Les inhibiteurs de l'autophagie peuvent bloquer ce processus, ce qui en fait des outils précieux pour étudier le rôle de l'autophagie dans les maladies et développer des stratégies thérapeutiques. Chez CymitQuimica, nous proposons des inhibiteurs de l'autophagie pour soutenir vos recherches en biologie cellulaire, oncologie et maladies neurodégénératives.
1494 produits trouvés pour "Autophagie"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
CXCR4 antagonist 3
CXCR4 antagonist 3, aka compound 12a, has 11 nM IC50, shares TIQ15 traits, and is promising in HIV research.Formule :C22H31N5Couleur et forme :SolidMasse moléculaire :365.52BRD5631
CAS :BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway.Formule :C30H35N3O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :501.62LC3B recruiter 1
CAS :LC3B recruiter 1 (compound 33R) is an LC3B recruiting fragment. It directly interacts with LC3B, exhibiting a Kd value of 2.87 µM.Formule :C14H10ClN3O2Couleur et forme :SolidMasse moléculaire :287.701LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Formule :C24H26F2N4O2SCouleur et forme :SolidMasse moléculaire :472.55DQ661
CAS :DQ661 is a potent inhibitor of PPT1 and a dimeric quinacrine autophagy (autophagy) inhibitor. It effectively suppresses the activity of mTORC1 and reduces protein expression levels of pS6K T389 and pS6 S240-244. Additionally, DQ661 exhibits anticancer properties.Formule :C41H47Cl2N5O2Couleur et forme :SolidMasse moléculaire :712.75ST-539
CAS :ST-539 is an inhibitor of the deubiquitinating enzyme USP30, with an IC50 of 0.37 μM. It enhances the ubiquitination of mitochondrial proteins and induces mitophagy (autophagy), thereby regulating mitochondrial homeostasis. ST-539 is applicable for research in neurodegenerative diseases.Formule :C30H31N3O4SCouleur et forme :SolidMasse moléculaire :529.65Rosiglitazone sodium
CAS :Rosiglitazone sodium is an effective and selective PPARγ activator, with EC50 values of 30 nM for PPARγ1, 100 nM for PPARγ2, and 60 nM for PPARγ. It also has an approximate Kd of 40 nM for PPARγ. Additionally, Rosiglitazone sodium acts as a regulator of TRP channels, inhibiting the activities of TRPM2 and TRPM3, while activating TRPC5.Formule :C18H18N3NaO3SCouleur et forme :SolidMasse moléculaire :379.41ACT-672125
CAS :ACT-672125: Potent CXCR3 blocker, may treat autoimmunity, safe with dose-dependent efficacy in lung inflammation.Formule :C25H25F3N10O2SCouleur et forme :SolidMasse moléculaire :586.59SRI-31255
CAS :SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Formule :C15H14N4Couleur et forme :SolidMasse moléculaire :250.30CCX662
CAS :CCX662 is a CXCR7 antagonist. It inhibits the binding of 125I-CXCL12 to CXCR7 with an IC50 of 9 nM. This compound is suitable for use in cancer research.Formule :C28H37N5O4SCouleur et forme :SolidMasse moléculaire :539.69PARL-IN-1
PARL-IN-1: Strong PARL blocker, IC50 28 nM, boosts PINK1/Parkin mitophagy.Formule :C40H58N6O7Couleur et forme :SolidMasse moléculaire :734.92CXCR2 antagonist 4
CXCR2 antagonist 4 inhibits CXCR2 (IC50: 0.13 μM) and CXCL8-induced calcium rise (IC50: 27 μM), promising for cancer research.Formule :C15H14F2N4OS2Couleur et forme :SolidMasse moléculaire :368.424-FPBUA
CAS :4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.Formule :C31H23FO7Couleur et forme :SolidMasse moléculaire :526.51ACT-777991
CAS :ACT-777991: oral CXCR3 blocker, stable in microsomes/hepatocytes, inhibits T-cell migration to CXCL11.Formule :C20H20F6N8O2SCouleur et forme :SolidMasse moléculaire :550.48(R)-SCH 546738
CAS :(R)-SCH 546738, the R-isomer of SCH 546738, is a non-competitive, orally active antagonist targeting the CXCR3 receptor, exhibiting a K_i of 0.4 nM for the human CXCR3 receptor.Formule :C23H31Cl2N7OCouleur et forme :SolidMasse moléculaire :492.45LRRK2-IN-2
CAS :LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Formule :C23H23Cl2F3N6O2Couleur et forme :SolidMasse moléculaire :543.37HDAC10-IN-1
HDAC10-IN-1 is a potent, selective HDAC10 inhibitor (IC50=58 nM) affecting autophagy in FLT3-ITD+ acute myeloid leukemia cells.Formule :C18H23N3O2Couleur et forme :SolidMasse moléculaire :313.39CXCR7 antagonist-1 hydrochloride
CAS :CXCR7 antagonist-1 hydrochloride, Inhibits SDF-1 (CXCL12) or I-TAC binding to CXCR7, used for tumor and inflammation research.Formule :C21H20ClFN6ODegré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :426.87Stauprimide
CAS :Stauprimide inhibits MYC by blocking NME2, reducing MYC transcription in ESCs.Formule :C35H28N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :584.62BRD1991
CAS :BRD1991 is a chemical compound that specifically disrupts the interaction between Beclin 1 and Bcl-2, thereby inducing autophagy.Formule :C33H35Cl2N3O4Couleur et forme :SolidMasse moléculaire :608.55
